Fordyce Marshall's Form 4 filing
Vera Therapeutics, Inc. (VERA) · filed Feb 27, 2025
- Accession no.
- 0001415889-25-005841
- Filed
- Feb 27, 2025
- Trade date
- Feb 21-26, 2025
- Filing delay
- 6 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $546.9K. It was filed 6 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fordyce MarshallCIK 0001859453 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 21, 2025 | Class A Common Stock | SSaleDisposed | −10,613 | $27.89 | −$295,996.57 | 213,740 | Direct | |
| Feb 26, 2025 | Class A Common Stock | SSaleDisposed | −7,975 | $27.55 | −$219,711.25 | 205,765 | Direct | |
| Feb 26, 2025 | Class A Common Stock | SSaleDisposed | −1,100 | $28.32 | −$31,152 | 204,665 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.